Literature DB >> 6412349

Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.

L J Catoggio, R P Skinner, P J Maddison.   

Abstract

To determine the clinical significance of anti-centromere (ACA) and anti Scl-70 antibodies in an English population with connective tissue diseases, we examined the sera of 150 patients, including 40 with systemic sclerosis (SS), who were prospectively studied on the same clinical protocol in our connective tissue disease clinic. ACA was present in 44% of the CREST patients as opposed to only 12% of those with SS and diffuse skin involvement. Only two patients without SS had ACA. Anti Scl-70 was detected in 20% of the patients with SS and only two of those with other connective tissue diseases. We confirmed the specificity of these antibodies for SS. Either anti Scl-70 or ACA was present in half the patients with SS and their presence may represent a useful aid to diagnosis of this disease in patients presenting with Raynaud's phenomenon or an undifferentiated connective tissue disease. While less than half the CREST patients had ACA, this antibody appears to identify those patients within the CREST variant with skin involvement confined to sclerodactyly as opposed to those with acrosclerosis. These patients, however, did not differ in the degree of visceral involvement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6412349     DOI: 10.1007/BF00541227

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

1.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

2.  Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

3.  Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.

Authors:  G Clark; M Reichlin; T B Tomasi
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Serological markers in progressive systemic sclerosis: clinical correlations.

Authors:  L J Catoggio; R M Bernstein; C M Black; G R Hughes; P J Maddison
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

5.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.

Authors:  R M Bernstein; J C Steigerwald; E M Tan
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06
  9 in total
  10 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

3.  Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.

Authors:  H H Guldner; C Szostecki; H P Vosberg; H J Lakomek; E Penner; F A Bautz
Journal:  Chromosoma       Date:  1986       Impact factor: 4.316

4.  Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.

Authors:  A Aeschlimann; O Meyer; P Bourgeois; T Haim; N Belmatoug; E Palazzo; M F Kahn
Journal:  Ann Rheum Dis       Date:  1989-12       Impact factor: 19.103

Review 5.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

6.  Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

Authors:  G R Harvey; S Butts; A L Rands; Y Patel; N J McHugh
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

7.  Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma).

Authors:  J D Reveille; D Owerbach; R Goldstein; R Moreda; R A Isern; F C Arnett
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

8.  Differential isotype recognition of two centromere associated polypeptides by immunoblotting in connective tissue disease.

Authors:  N J McHugh; I E James; P J Maddison
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

9.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?

Authors:  Marina Scolnik; Luis J Catoggio; Eliana Lancioni; Mirtha R Sabelli; Carla M Saucedo; Josefina Marin; Enrique R Soriano
Journal:  Int J Rheumatol       Date:  2014-11-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.